123 related articles for article (PubMed ID: 14727234)
1. Proceedings of the 3rd International Cytoprotection Investigators' Congress. May 15-18, 2003, Nevis, West Indies.
Semin Oncol; 2003 Dec; 30(6 Suppl 18):1-108. PubMed ID: 14727234
[No Abstract] [Full Text] [Related]
2. Proceedings of the Fourth International Cytoprotection Investigators' Congress. May 2004. Philadelphia, Pennsylvania, USA.
Semin Oncol; 2004 Dec; 31(6 Suppl 18):1-73. PubMed ID: 15801121
[No Abstract] [Full Text] [Related]
3. Proceedings of the 2nd International Cytoprotection Investigators' Congress. June 6-9, 2002. St Thomas, US Virgin Islands, USA.
Semin Oncol; 2002 Dec; 29(6 Suppl 19):1-83. PubMed ID: 12577235
[No Abstract] [Full Text] [Related]
4. Cytoprotection for radiation-associated normal tissue injury.
Mao J; Fatunase OA; Marks LB
Cancer Treat Res; 2008; 139():307-27. PubMed ID: 18236722
[No Abstract] [Full Text] [Related]
5. Established and emerging uses of cytoprotection in head and neck cancer.
Rosenthal DI
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):129-30. PubMed ID: 16490868
[No Abstract] [Full Text] [Related]
6. [Optimal tumor therapy with cytoprotection by ETHYOL (Amifostine). 32nd Annual Session of the American Society of Clinical Oncology in Philadelphia 18-21 May 1996].
Dtsch Med Wochenschr; 1996 Sep; 121(36 Suppl Fur Die):1-6. PubMed ID: 9417379
[No Abstract] [Full Text] [Related]
7. New approaches to preventing xerostomia.
J Support Oncol; 2006 Feb; 4(2):87-8. PubMed ID: 16499130
[No Abstract] [Full Text] [Related]
8. The role of amifostine as a radioprotector.
Wasserman TH; Brizel DM
Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
[TBL] [Abstract][Full Text] [Related]
9. Potential for use of amifostine in cervical cancer.
Small W
Semin Oncol; 2002 Dec; 29(6 Suppl 19):34-7. PubMed ID: 12577241
[TBL] [Abstract][Full Text] [Related]
10. Does amifostine have a role in chemoradiation treatment?
Brizel DM; Overgaard J
Lancet Oncol; 2003 Jun; 4(6):378-81. PubMed ID: 12788413
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Anné PR
Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
[TBL] [Abstract][Full Text] [Related]
12. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Bourhis J; Rosine D
Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
[TBL] [Abstract][Full Text] [Related]
13. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Bourhis J; Blanchard P; Maillard E; Brizel DM; Movsas B; Buentzel J; Langendijk JA; Komaki R; Swan Leong S; Levendag P; Pignon JP
J Clin Oncol; 2011 Jun; 29(18):2590-7. PubMed ID: 21576630
[TBL] [Abstract][Full Text] [Related]
14. Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Myerson R; Zobeiri I; Birnbaum E; Dietz D; Fleshman J; Kodner I; Picus J; Ratkin G
Semin Oncol; 2002 Dec; 29(6 Suppl 19):29-33. PubMed ID: 12577240
[TBL] [Abstract][Full Text] [Related]
15. Indications for use of amifostine.
Santolaya-Perrin R; Castillo-Romera I; Requena-Caturla T
Am J Health Syst Pharm; 1998 Sep; 55(17):1827-8. PubMed ID: 9775347
[No Abstract] [Full Text] [Related]
16. [Current status of prevention and management of radiation-induced xerostomia].
Ma DY; Qiu WL; Zhang CP
Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Feb; 45(2):121-3. PubMed ID: 20368009
[No Abstract] [Full Text] [Related]
17. Specific protection of different normal tissues.
Rasey JS; Spence AM; Badger CC; Krohn KA; Vera DM; Livesey JC
Pharmacol Ther; 1988; 39(1-3):33-43. PubMed ID: 2849132
[No Abstract] [Full Text] [Related]
18. Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy.
Koukourakis MI; Kyrgias G; Papadopoulou A; Panteliadou M; Giatromanolaki A; Sivridis E; Mavropoulou S; Kalogeris K; Nassos P; Milioudis N; Touloupidis S
Anticancer Res; 2011 May; 31(5):1745-51. PubMed ID: 21617234
[TBL] [Abstract][Full Text] [Related]
19. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
Braaksma M; Levendag P
Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
[TBL] [Abstract][Full Text] [Related]
20. Amifostine.
Rasey JS
Cancer Biother Radiopharm; 1999 Oct; 14(5):331-5. PubMed ID: 10850317
[No Abstract] [Full Text] [Related]
[Next] [New Search]
